Radiofrequency ablation, which is also known as rhizotomy, is a non-surgical, minimally invasive procedure that utilizes heat to minimize or stop the overall transmission of pain. Radiofrequency waves “burn,” or ablate, the nerve that is creating the pain, essentially by eradicating the overall transmission of pain signals to the brain. In other words, radiofrequency ablation is a minimally invasive procedure that primarily kills the nerve fibres that carry the pain signals to the brain. It can give lasting relief to people with chronic pain, especially in the neck, lower back, and arthritic joints. If any individual suffered from recurrent pain and had experienced good relief with a nerve block injection, then the individual may be a candidate for radiofrequency ablation.
This procedure is widely used to cure chronic pain and conditions like arthritis of the spine (spondylosis) and sacroiliitis. It is also utilized to cure knee, neck,pelvic, back, and peripheral nerve pain. The key benefits of radiofrequency ablation involve: immediate pain relief, decreased need for pain medication, avoiding surgery, improved function, little to no recovery time, and a quicker return to work and various other activities.
All the Radiofrequency Ablation devices mostly use an electro surgical generator that is connected to the bipolar electrode arrays in order to deliver the thermal energy to the tissue. Electricity propagates through the tissues in between the alternating positive & negative poles along with the electrode arrays of the Radiofrequency Ablationdevice within the radiofrequency range of 450 to 500 kilo Hz. This current generates the thermal energy within the tissue in direct contact with the RF (radiofrequency) electrode, thereby resulting in coagulation necrosis of the targeted tissues. The spacing & geometry of the electrodes on the Radiofrequency Ablationdevice and the preset parameters (power, energy) within the Radiofrequency Ablationgenerator enable the overall achievement of a consistent depth of the ablation. For example, in the entire treatment of the mucosal pathologic conditions, the dosimetry is primarily designed to produce an ablation depth to the muscularis mucosae that are around 700-800 μm deep.
The Market for Global Radio Frequency Ablation Devices is anticipated to achieve a remarkable landmark of USD 10.726 billion by the end of 2030 from USD 3.531 billion in 2020, at a CAGR of 11.73 percent during the forecasted period. Apart from the rising number of cases ofcancer and CVDs, the increase in the overall demand for pain management (such as relief from arthritis and several other chronic pain disorders by medicines) is also propelling the total growth of the market to a great extent.
Recent Developmentsrelated to the Radiofrequency Ablation Devices Market:
- On the 1st of June, 2020, Boston Scientific inaugurated the DIRECTSENSE Technology, which has offered the electrophysiologists the first-ever visualization and local measurement of the tissue responses to the Radiofrequency Ablation Devices.
On the 27th of Feb, 2019, Medtronic gained the FDA clearance to launch the Accurian radiofrequency ablation platform, which is extremely efficient in terms of conducting Radiofrequencyablation of the nerve tissues.